Metastatic castration-sensitive prostate cancer (mCSPC) is a form of advanced prostate cancer that may still be responsive to hormone treatment, but is more sensitive. Revive Research Institute is looking for patients who have mCSPC who have a type of gene mutation called DNA damage Repair (DDR) defects.
The goal of this research study is to investigate the efficacy of an investigational drug in combination with an FDA-approved hormone therapy to better treat patients with DDR-deficient mCSPC. The investigational drug is intended to stop the activity of certain proteins that are found in all cells, normal and cancerous, but are involved in the repair of specific DNA errors.
- Male adults 18 years of age or older
- Confirmed diagnosis of adenocarcinoma of the prostate
- Confirmation of DDR gene mutation
- Surgically or medically castrated
- Additional criteria may apply
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.